Q3 2018 FibroGen Inc Earnings Call
Conference Call FibroGen Inc
FibroGen Inc Conference call will be held on Nov 8, 2018. During the earnings conference call's session FibroGen Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact FibroGen Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a research-based, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic agents to treat serious unmet medical needs. We have capitalized on our extensive experience in fibrosis and hypoxia inducible factor ("HIF"), biology to generate multiple programs targeting various therapeutic areas. Our most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases ("HIF-PHs"), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). Our second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer, Duchenne muscular dystrophy ("DMD") and liver fibrosis.Read more Conference Call